NO984503L - Eprosartandihydrat og en fremgangsmÕte for dets fremstilling og formulering - Google Patents

Eprosartandihydrat og en fremgangsmÕte for dets fremstilling og formulering

Info

Publication number
NO984503L
NO984503L NO984503A NO984503A NO984503L NO 984503 L NO984503 L NO 984503L NO 984503 A NO984503 A NO 984503A NO 984503 A NO984503 A NO 984503A NO 984503 L NO984503 L NO 984503L
Authority
NO
Norway
Prior art keywords
formulation
preparation
eprosartan
dihydrate
eprosartan dihydrate
Prior art date
Application number
NO984503A
Other languages
English (en)
Other versions
NO311760B1 (no
NO984503D0 (no
Inventor
Nageswara R Palepu
Gopadi M Venkatesh
Sarma Duddu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO984503(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO984503L publication Critical patent/NO984503L/no
Publication of NO984503D0 publication Critical patent/NO984503D0/no
Publication of NO311760B1 publication Critical patent/NO311760B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19984503A 1996-03-29 1998-09-28 Eprosartandihydrat, anvendelse og fremgangsmåte for fremstilling derav, og farmasöytisk preparat inneholdende dette NO311760B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29
PCT/US1997/004877 WO1997036874A1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Publications (3)

Publication Number Publication Date
NO984503L true NO984503L (no) 1998-09-28
NO984503D0 NO984503D0 (no) 1998-09-28
NO311760B1 NO311760B1 (no) 2002-01-21

Family

ID=21765344

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19984503A NO311760B1 (no) 1996-03-29 1998-09-28 Eprosartandihydrat, anvendelse og fremgangsmåte for fremstilling derav, og farmasöytisk preparat inneholdende dette
NO2002005C NO2002005I1 (no) 1996-03-29 2002-07-19 Eprosartan

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2002005C NO2002005I1 (no) 1996-03-29 2002-07-19 Eprosartan

Country Status (35)

Country Link
EP (1) EP0889880B1 (no)
JP (1) JP4316013B2 (no)
CN (2) CN1214682A (no)
AP (1) AP901A (no)
AR (1) AR006439A1 (no)
AT (1) ATE239723T1 (no)
AU (1) AU726694B2 (no)
BG (1) BG64095B1 (no)
BR (1) BR9708336A (no)
CA (1) CA2250395C (no)
CZ (1) CZ293345B6 (no)
DE (1) DE69721749T2 (no)
DK (1) DK0889880T3 (no)
DZ (1) DZ2199A1 (no)
EA (1) EA001958B1 (no)
EG (1) EG23889A (no)
ES (1) ES2198564T3 (no)
HU (1) HU228263B1 (no)
ID (1) ID16507A (no)
IL (1) IL126319A0 (no)
MA (1) MA24437A1 (no)
MY (1) MY117682A (no)
NO (2) NO311760B1 (no)
NZ (1) NZ332008A (no)
OA (1) OA11176A (no)
PL (1) PL188816B1 (no)
PT (1) PT889880E (no)
RO (1) RO118870B1 (no)
SK (1) SK282346B6 (no)
TR (1) TR199801954T2 (no)
TW (1) TW434239B (no)
UA (1) UA49880C2 (no)
UY (1) UY24504A1 (no)
WO (1) WO1997036874A1 (no)
ZA (1) ZA972686B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0991647B1 (en) * 1997-06-27 2002-09-04 Smithkline Beecham Corporation Eprosartan monohydrate
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
PL340587A1 (en) * 1997-11-17 2001-02-12 Smithkline Beecham Corp Oral preparations of high therapeutic substance content with instantaneous or modifiable release of such substance and methods of obtaining them
ES2214013T3 (es) 1998-03-04 2004-09-01 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
AU763309B2 (en) * 1998-07-20 2003-07-17 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
WO2000027396A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
WO2000066161A1 (en) * 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
CA2405793A1 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of organic compounds
PL370270A1 (en) * 2001-11-23 2005-05-16 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2003097099A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
RS20050590A (sr) 2003-01-31 2007-09-21 Sankyo Company Limited, Lek za profilaksu i tretman arterioskleroze i hipertenzije
US8361507B2 (en) 2007-07-25 2013-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) * 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
EP0563238B1 (en) * 1990-12-14 2002-05-22 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
PL188816B1 (pl) 2005-04-29
AR006439A1 (es) 1999-08-25
DK0889880T3 (da) 2003-09-01
HUP9902769A3 (en) 2000-04-28
CZ293345B6 (cs) 2004-04-14
BG64095B1 (bg) 2003-12-31
SK132298A3 (en) 1999-03-12
HUP9902769A2 (hu) 2000-03-28
IL126319A0 (en) 1999-05-09
DE69721749D1 (de) 2003-06-12
EG23889A (en) 2007-12-12
AU2547097A (en) 1997-10-22
PL329046A1 (en) 1999-03-01
TW434239B (en) 2001-05-16
JP2000508632A (ja) 2000-07-11
AP901A (en) 2000-11-23
UY24504A1 (es) 1997-09-19
PT889880E (pt) 2003-09-30
SK282346B6 (sk) 2002-01-07
EP0889880A1 (en) 1999-01-13
HK1016594A1 (en) 1999-11-05
BR9708336A (pt) 1999-08-03
EA199800873A1 (ru) 1999-02-25
OA11176A (en) 2003-05-13
CZ310198A3 (cs) 1999-03-17
HU228263B1 (en) 2013-02-28
DE69721749T2 (de) 2004-03-25
CA2250395C (en) 2005-09-06
NO311760B1 (no) 2002-01-21
NO2002005I1 (no) 2002-09-02
CN1332167A (zh) 2002-01-23
MA24437A1 (fr) 1998-10-01
WO1997036874A1 (en) 1997-10-09
BG102822A (en) 1999-11-30
AU726694B2 (en) 2000-11-16
AP9700956A0 (en) 1997-04-30
TR199801954T2 (xx) 1998-12-21
JP4316013B2 (ja) 2009-08-19
UA49880C2 (uk) 2002-10-15
EA001958B1 (ru) 2001-10-22
ZA972686B (en) 1997-09-29
ID16507A (id) 1997-10-02
MY117682A (en) 2004-07-31
CN1214682A (zh) 1999-04-21
ATE239723T1 (de) 2003-05-15
EP0889880B1 (en) 2003-05-07
ES2198564T3 (es) 2004-02-01
RO118870B1 (ro) 2003-12-30
NO984503D0 (no) 1998-09-28
NZ332008A (en) 1999-05-28
CA2250395A1 (en) 1997-10-09
DZ2199A1 (fr) 2002-12-03
EP0889880A4 (en) 1999-06-23

Similar Documents

Publication Publication Date Title
NO984503D0 (no) Eprosartandihydrat og en fremgangsmÕte for dets fremstilling og formulering
NO994392L (no) Oksiranderivat og fremgangsmate for dets fremstilling
DK0739898T3 (da) Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO976072D0 (no) Propiofenonderivater og fremgangsmåte for fremstilling derav
NO924768D0 (no) Farmasoeytisk preparat og fremgangsmaate for dets fremstilling
FI19992360L (fi) Tuote ja menetelmä sen valmistamiseksi
DK0926952T3 (da) Antimikrobiel sammensætning og fremgangsmåde til fremstilling deraf
EE9900014A (et) Erütromütsiinid ja nende valmistamise protsess
NO20000602D0 (no) Krembasert matsammensetning og fremgangsmÕte for fremstilling derav
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
HUP0000066A3 (en) Olanzapine dihydrate and process for preparing olanzapine form ii
NO20002202D0 (no) Støpte polyolefin- og polyfenyloksidprodukter og fremgangsmÕte til fremstilling derav
DK1054672T3 (da) Morfinsulfatmikrogranula, fremgangsmåde til fremstilling deraf og farmaceutiske præparater
DK0735042T3 (da) Maltitolsammensætning og fremgangsmåde til fremstilling deraf
DK0909271T3 (da) Indolyl-pyrrolylidenmethylpyrrolderivater og en fremgangsmåde til fremstilling deraf
IS1826B (is) Aðferð til að framleiða felódipín og aðferð til að framleiða lyfjablöndu
NO20000577D0 (no) Eprosartanarginyl-ladning-noeytraliseringskompleks g en fremgangsmåte for dets fremstilling og formuulering
FI961555L (fi) Menetelmä keraamisten tuotteiden valmistamiseksi
NO993863L (no) Forbindelser og fremgangsmÕte for fremstilling av substituerte 4-fenyl-4-cyanocycloheksansyrer
NO960766D0 (no) Nytt protein og fremgangsmåte for fremstilling av dette
FI941992L (fi) Menetelmä ja laitteisto betonituotteiden valmistamiseksi
FI991165L (fi) Menetelmä ja laite betonituotteen valmistamiseksi sekä betonituote
NO970768D0 (no) Alkylert polyallylamin og fremgangsmåte for fremstilling av dette
IL129180A0 (en) Method and pharmaceutical composition for wound healing

Legal Events

Date Code Title Description
MK1K Patent expired